Overview

Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

Status:
NOT_YET_RECRUITING

Trial end date:
2025-05-31

Target enrollment:

Participant gender:

Summary

To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people

Phase:

PHASE2

Details

Lead Sponsor:

Changchun BCHT Biotechnology Co.

Collaborators:

Anning City First People's Hospital
Beijing Contreke Statistical Technology Co., LTD
Military Science Zhengyuan (Beijing) Pharmaceutical Research Co., LTD
The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
Yunnan Central Hospital